Nakasone Elizabeth S, Hurvitz Sara A, McCann Kelly E
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Drugs Context. 2018 Feb 12;7:212520. doi: 10.7573/dic.212520. eCollection 2018.
Breast cancer is the most prevalent malignancy in women and the second most common cause of cancer-related death worldwide. Despite major innovations in early detection and advanced therapeutics, up to 30% of women with node-negative breast cancer and 70% of women with node-positive breast cancer will develop recurrence. The recognition that breast tumors are infiltrated by a complex array of immune cells that influence their development, progression, and metastasis, as well as their responsiveness to systemic therapies has sparked major interest in the development of immunotherapies. In fact, not only the native host immune system can be altered to promote potent antitumor response, but also its components can be manipulated to generate effective therapeutic strategies. We present here a review of the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.
乳腺癌是女性中最常见的恶性肿瘤，也是全球癌症相关死亡的第二大常见原因。尽管在早期检测和先进治疗方面有重大创新，但高达30%的淋巴结阴性乳腺癌女性和70%的淋巴结阳性乳腺癌女性仍会出现复发。认识到乳腺肿瘤被一系列复杂的免疫细胞浸润，这些免疫细胞会影响肿瘤的发生、发展、转移以及对全身治疗的反应，这引发了人们对免疫疗法开发的浓厚兴趣。事实上，不仅可以改变天然宿主免疫系统以促进有效的抗肿瘤反应，还可以操纵其组成部分以产生有效的治疗策略。我们在此对乳腺癌免疫疗法的主要方法进行综述，包括成功与失败案例，以及即将出现的新疗法。
